Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 80181 refers to a laboratory test specifically designed to monitor therapeutic levels of flecainide, which is classified as an antiarrhythmic medication. Flecainide is primarily utilized in the management of various cardiac conditions, including paroxysmal supraventricular tachycardia, atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias. The purpose of therapeutic drug monitoring is to ensure that the dosage of flecainide is optimized for each patient, thereby minimizing the risk of toxicity and ensuring adherence to the prescribed treatment regimen. Flecainide is administered orally and is known for its rapid absorption, achieving peak plasma levels approximately three hours post-administration. Steady-state concentrations are typically reached within three to five days of consistent dosing. The elimination of flecainide from the body occurs primarily through liver metabolism and renal excretion, with an average half-life of about 20 hours; however, this can vary significantly, ranging from 12 to 27 hours in adults, and approximately 8 hours in children. It is important to note that any impairment in liver or kidney function can significantly affect the elimination process of the drug. Patients may experience various adverse effects, including dizziness, visual disturbances, palpitations, nausea, fatigue, headaches, and shortness of breath. Therapeutic trough levels for flecainide are established between 0.2 to 1.0 mcg/mL, which are considered effective for suppressing premature ventricular contractions. Levels exceeding 1.0 mcg/mL indicate potential toxicity, which can manifest through severe symptoms such as hallucinations, joint pain, adverse cardiac events (including bradycardia, conduction defects, or asystole), respiratory failure, hypotension, and in extreme cases, death. To accurately assess the drug concentration, a blood sample is collected immediately before the next scheduled dose, processed by centrifugation to separate serum or plasma from blood cells, and analyzed using quantitative liquid chromatography-tandem mass spectrometry.
© Copyright 2026 Coding Ahead. All rights reserved.
The laboratory test associated with CPT® Code 80181 is indicated for the following conditions:
The procedure for monitoring therapeutic levels of flecainide involves several critical steps to ensure accurate measurement of the drug concentration in the patient's blood. First, a blood sample is drawn from the patient immediately prior to the next scheduled dose of flecainide. This timing is crucial as it allows for the measurement of the trough level, which is the lowest concentration of the drug in the bloodstream. Following the blood draw, the sample is processed by centrifugation, a technique that separates the serum or plasma from the blood cells. This separation is essential for obtaining a clear sample that can be accurately analyzed. The resulting serum or plasma is then placed in a plastic vial to prevent any contamination or degradation of the sample. The analysis of the flecainide concentration is performed using quantitative liquid chromatography-tandem mass spectrometry, a highly sensitive and specific method that allows for precise measurement of drug levels. This analytical technique is capable of detecting even low concentrations of flecainide, ensuring that the results are reliable for therapeutic monitoring. The entire process, from blood collection to analysis, is designed to provide healthcare professionals with the necessary information to adjust dosages as needed, monitor patient compliance, and prevent potential toxicity.
After the blood sample has been collected and processed, there are no specific post-procedure care requirements for the patient related to the blood draw itself. However, it is essential for healthcare providers to review the results of the flecainide level promptly to make any necessary adjustments to the patient's medication regimen. Patients should be monitored for any signs of adverse effects associated with flecainide, especially if the levels indicate potential toxicity. Regular follow-up appointments may be necessary to ensure ongoing therapeutic monitoring and to assess the patient's response to treatment. Additionally, healthcare providers should educate patients about the importance of adhering to their prescribed medication schedule and reporting any unusual symptoms that may arise during treatment.
| Short Descr | DRUG ASSAY FLECAINIDE | Medium Descr | DRUG ASSAY FLECAINIDE | Long Descr | Flecainide | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2021-01-01 | Added | Code added. |
Get instant expert-level medical coding assistance.